•
Jun 30, 2020
Annexon Q2 2020 Earnings Report
Announced second quarter 2020 financial results and recent highlights.
Key Takeaways
Annexon reported second quarter results, highlighting the completion of a $263M IPO in July and plans to initiate four new clinical trials by year-end. Cash and cash equivalents were $124.8 million as of June 30, 2020. Net loss attributable to common stockholders was $12.5 million or $28.87 per share for the quarter ended June 30, 2020.
Completed $263M IPO in July, and private financing in late June
Planning to initiate four new clinical trials by year-end, including in three expanded indications for ANX005 and first-in-human trial of ANX009
Phase 2 trials of ANX005 in GBS and ANX007 in GA remain on track for 2021
Michael Overdorf was appointed chief business officer to oversee corporate development and commercial strategy efforts